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ABSTRACT
Experimental, epidemiological and clinical evidence implicates insulin resistance and its
accompanying hyperinsulinaemia in the development of cancer, but the relative importance of
these disturbances in cancer remains unclear. There are, however, theoretical mechanisms by
which hyperinsulinaemia could amplify such growth-promoting effects as insulin may have, as well
as the growth-promoting effects of other, more potent, growth factors. Hyperinsulinaemia may
also induce other changes, particularly in the IGF (insulin-like growth factor) system, that could
promote cell proliferation and survival. Several factors can independently modify both cancer risk
and insulin resistance, including subclinical inﬂammation and obesity. The possibility that some
of the effects of hyperinsulinaemia might then augment pro-carcinogenic changes associated with
disturbances in these factors emphasizes how, rather than being a single causative factor, insulin
resistance may be most usefully viewed as one strand in a network of interacting disturbances that
promote the development and progression of cancer.
INTRODUCTION
Insulin resistance is a state of reduced sensitivity
of insulin-responsive tissues to insulin and its key
consequences include an impaired ability of insulin
to suppress hepatic glucose production and stimulate
peripheral glucose elimination. Circulating glucose levels
would, therefore, be expected to rise with insulin
resistance, but glucose is insulin’s principal secretagogue
and, providing β-cell function is adequate, insulin
secretion increases to overcome insulin resistance and
glucose levels are normalized. The resulting ‘com-
pensatory hyperinsulinaemia’ is a hallmark of insulin
resistance.
Insulin resistance coincides with an increased risk
of cancer in a variety of conditions, including aging,
physical inactivity [1], obesity [2], central body fat
distribution [3], Type 2 diabetes [4], hyperglycaemia [5],
the metabolic syndrome [6], liver disease [7], subclinical
inﬂammation [8], acromegaly [9], a high-glycaemic-
index diet [10] and a high-saturated-fat diet [11], and
there is extensively reviewed evidence linking measures
associated with insulin resistance with the subsequent
development ofcancer orpre-cancerouschanges [12–21].
These reviews have, however, tended to focus on speciﬁc
conditions, e.g. diabetes, obesity or colorectal cancer, or
on epidemiological rather than experimental evidence.
The present review begins by highlighting key aspects
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oftheexperimental,epidemiologicalandclinicalevidence
thatjustifyanin-depthconsiderationofinsulinresistance
and hyperinsulinaemia as factors in carcinogenesis. It
then examines the various mechanisms by which insulin
resistanceanditsaccompanyinghyperinsulinaemiacould
have an impact on cancer risk. The review also makes
a distinction between promotion of cancer by insulin
resistance and hyperinsulinaemia and promotion of
cancer by conditions that coincidentally cause insulin
resistance and hyperinsulinaemia.
EXPERIMENTAL, EPIDEMIOLOGICAL AND




Azoxymethane induction of colon cancer or pre-
cancerous aberrant crypt foci in the rat has provided
the most widely used experimental model with which
links between insulin resistance and cancer have been
evaluated. Tumorigenesis in this model is enhanced by
injection of medium-acting insulin [22,23], and calorie
restriction, perhaps the most familiar means of reducing
insulinresistance,diminishesthedevelopmentofaberrant
crypt foci [24]. Calorie restriction is also effective in
other animal models [25,26]. Low fat in the diet provides
additionalprotection[27]andthisemphasizesfurtherthe
possible importance of insulin resistance, given that low-
fat diets are associated with reduced insulin resistance
independent of calorie content [28]. Conversely, high
calorie intake correlates signiﬁcantly with pre-cancerous
changes [29], and this effect is again modulated by
dietary composition, the most tumorigenic being a high-
fat diet [30]. It is worth noting that, in an animal
model of breast cancer, the presence of obesity had no
apparent effect on mammary tumour development, but
thecarcinogenemployedwasmoreabletopromotecolon
cancer [31]. Insulin resistance and hyperinsulinaemia are
typical of obesity, so this observation draws attention to
the possibility that insulin resistance may be particularly
important in colon cancer.
Bruce and co-workers [32] have extended the dietary
studies to include an evaluation of accompanying
changes in insulin resistance and insulinaemia. The
development of colonic aberrant crypt foci was preceded
by insulin resistance and hyperinsulinaemia, and there
was a signiﬁcant positive relationship between the
size of aberrant crypt foci and non-fasting insulin
concentrations[29].Astrongerrelationshipwasobserved
with increasing OGTT (oral glucose tolerance test)
glucose concentrations which, when resulting from
dietary modiﬁcation, would be expected to reﬂect
increasing insulin resistance. In subsequent experiments,
Table 1 Correlation coefﬁcients for the relationships
between aberrant crypt foci and indices and measures
of insulin resistance and insulinaemia in Fischer 344 rats
initiated by azoxymethane and given diets differing in
calorie and saturated fat content (Koohestani et al. [29])
or saturated fat content (Tran et al. [33])
ACF, aberrant crypt foci; AUC, area under the curve.
Correlation with
Study ACF size/number Signiﬁcance
Koohestani et al. [29] (n=98)
Fasting plasma insulin 0.39 <0.01
OGTT glucose AUC 0.67 <0.001
Tran et al. [33] (n=24)
OGTT 180 min insulin 0.42 <0.05
Clamp insulin sensitivity −0.52 <0.01
a positive relationship was observed between the
number of aberrant crypt foci and insulin concentrations
3 h following an oral glucose load, but a stronger
relationship was apparent with a direct measure of
insulin sensitivity obtained using the euglycaemic–
hyperinsulinaemic clamp [33]. The signiﬁcant correlates
of precursors of colon cancer were, therefore, those
that might be expected to express most accurately net
insulin exposure. Key ﬁndings from these experiments
are summarized in Table 1.
Epidemiological studies
A complicating factor in evaluating whether experi-
mental associations between insulin resistance and cell
proliferation and survival translate into increased risk
in humans has been the difﬁculty in assessing insulin
resistance, requiring as it does quantiﬁcation of the
rate of elimination of glucose from the blood relative
to the accompanying plasma insulin concentration.
Plasma insulin concentrations can, nevertheless, provide
a surrogate index since, in the presence of adequate β-cell
function, the degree of compensatory hyperinsulinaemia
is directly related to the degree of insulin resistance.
C-peptide may provide a more effective index of
insulinaemia as it is secreted simultaneously and in
equimolar quantities with insulin but has a longer plasma
half-life, which may render it less subject to individual
variation. Associations between insulin or C-peptide
and cancer have been evaluated in a number of studies.
Studies of colorectal cancer are divided between those
showing no association [34–38] or a signiﬁcant positive
association [3,39–44], although three studies have found
signiﬁcantly higher insulin or C-peptide concentrations
among patients in whom colorectal adenoma has been
detected [45–47], particularly in those with advanced
lesions [45]. As with colorectal cancer, studies are
divided for breast cancer (no association [48–56]; positive
association [57–64]), endometrial cancer (no association
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[65,66]; positive association [67–69]) and prostate cancer
(no association [70–72]; positive association [73,74]).
Two studies of pancreatic cancer both found a positive
association [75,76].
Studies of colorectal, breast, endometrial and pancre-
atic cancer were the subject of a meta-analysis by Pisani
[19] published in 2008. The majority of studies were
population-based and, for colorectal and endometrial
cancers, there was little difference between prospective
and cross-sectional studies. Pisani did, however, note
that, for breast cancer, prospective studies all showed
no association with insulin or C-peptide, with all of the
evidence for a positive association coming from cross-
sectional studies. Positive associations could, therefore,
reﬂect secondary effects of existing cancer in the cases.
However, more recently, two prospective analyses from
the U.S. Women’s Health Initiative Observational Study
have reported a positive association between insulin con-
centrations and incident breast cancer [60,61]. Import-
antly, one of these evaluated serial insulin measurements
[61],whichwouldbeexpectedtoprovideamoreaccurate
assessment of net insulin exposure than a single baseline
measure. The serially derived insulin measures showed
an appreciably stronger relationship with incident breast
cancer than the single baseline measurements.
Epidemiological studies of the relationships between
insulin, C-peptide and cancer vary considerably in study
design and the extent to which confounding factors
have been taken into account. However, the majority
standardized for the principal confounder, adiposity.
The extent to which there is a continuous or threshold
relationship between insulinaemia and cancer is difﬁcult
to assess, the majority of studies simply comparing risk
in the top and bottom percentiles. There is, however,
some evidence for a continuous relationship [43]. The
weight of epidemiological evidence, therefore, suggests
that hyperinsulinaemia (and, by implication, insulin
resistance) is a risk factor for cancer and it should be
noted that, with studies divided between those showing
no association or a positive association, the weight
of evidence favours a positive association. Only with
prostate cancer has there been any evidence for a lower
risk of cancer with elevated insulin levels [77,78]. Studies
of prostate cancer will be confounded by the low
androgen concentrations, and therefore lower risk of
prostate cancer, that may be found in association with
insulin resistance. Nevertheless, as mentioned above,
there are also studies showing no association [70–72] or a
positive association [73,74] between prostate cancer and
insulinaemia. Relative risks for all studies of colorectal,
breast, endometrial and pancreatic cancer in the meta-
analysis of Pisani [19] are summarized in Table 2, with
estimates for prostate cancer from the meta-analysis of
Hsing et al. [18].
Other indices of insulin resistance or hyper-
insulinaemia include plasma leptin concentrations, the
Table 2 Summary relative risk estimates for plasma insulin
or C-peptide as predictors of colorectal, breast, endometrial
and pancreatic cancer from the meta-analysis of Pisani [19]
and for insulin as a predictor of prostate cancer from the
meta-analysis of Hsing et al. [18]
CI, conﬁdence interval.
Type of cancer Relative risk (95% CI) Number of cases
Colorectal 1.35 (1.13–1.61) 1257
Breast 1.26 (1.06–1.48) 1164
Endometrial 1.11 (0.74–1.65) 388
Pancreatic 1.70 (1.10–2.63) 209
Prostate 1.53 (1.01–2.32) 220
coincident insulin-resistance-related cardiovascular risk
factors of the metabolic syndrome and polymorphisms
of the insulin signalling system. As with measures of
insulinaemia, studies are divided according to whether
they show no signiﬁcant association or a signiﬁcant
positive association between these indices and cancer risk
[12–18,79–81]. It is noteworthy, however, that for the
metabolic syndrome, which would be expected to reﬂect
long-term insulin resistance and hyperinsulinaemia, the
weight of evidence appears to favour a signiﬁcant
positive association [6,17,18,38,82–87]. It should also be
noted that insulin-resistance-related abnormalities may
be associated, not only with cancer itself, but also
with more aggressive cancer or with mortality from
cancer in those with existing cancer [88–92]. Equivocal
evidence regarding diabetes mellitus may reﬂect a lack
of discrimination between hypo- and hyper-insulinaemic
formsofdiabetesmellitus[17,93]andpossibledifferences
according to diabetes therapy [21] (see the next section).
Clinical evidence
Restoration of insulin action by a reduction in insulin
resistance and replacement of plasma insulin is central
to the treatment of diabetes mellitus, and monitoring
of the long-term effects of the different treatments
available has provided suggestive evidence regarding
links between insulin resistance, hyperinsulinaemia and
cancer. A number of insulin-sensitization agents have
recently become available, but only metformin has
been in use long enough for reliable conclusions to be
drawn regarding its effects on cancer in vivo. Metformin
augments signalling via AMPK (AMP-activated protein
kinase), resulting in inhibition of hepatic glucose and
lipid synthesis and increased muscle glucose uptake
[94]. Consequently less insulin is needed to achieve
these effects and a net insulin sensitization is apparent.
Additionally, AMPK activation can inhibit cell growth
and proliferation, possibly via inhibition of the mTOR
(mammalian target of rapamycin) complex [95], and
there are now several studies showing a reduced risk
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of cancer in patients treated with metformin [96–99]. It
could be argued, however, that this reﬂects metformin’s
intracellular actions rather than any effect it may have
on insulin resistance and hyperinsulinaemia. Moreover,
evidence from in vitro studies indicates that metformin
also has effects on cell proliferation via intracellular
targets other than AMPK [100,101].
Injectionofinsulinbypatientswithdiabetestocontrol
their blood glucose levels has been a mainstay of Type 1
diabetestherapyforover80 yearsandisalsoanimportant
option in the treatment of Type 2 diabetes. There is some
evidence that insulin therapy can augment colorectal
cancer risk in patients with Type 2 diabetes [102,103].
Importantly,oneofthesestudiescorrectedformetformin
use, this being likely to be more frequent in the non-
insulin-using controls and to be associated with lower
colorectal cancer risk [102]. Moreover, that study found
that risk increased signiﬁcantly with increasing duration
of chronic insulin use. Further suggestive evidence comes
from a study published recently based on a German
insurance fund cohort in which a signiﬁcant increase in
the risk of malignant neoplasm or cancer mortality was
observedwitheachS.D.increaseindoseofhumaninsulin
[104].
Recombinant DNA technology has enabled the
construction of insulin analogues with enhanced
absorption properties and a more sustained biological
effect on account of a higher afﬁnity of binding to
the insulin receptor. Such properties might also be
expected to enhance any effects insulin might have on
cellproliferationandsurvival.Adose-dependentincrease
in malignant tumour formation was observed in rats
injected with one of the earliest of these analogues to
be investigated, B10-Asp (AspB10 insulin), which has
an aspartate residue substituted at the B10 position of
the insulin molecule [105]. A 7-fold increase in the
rate of proliferation of cultured human cancer cells was
observed with this analogue [106], and similar effects
have been reported in vitro with other analogues [107].
Insulin analogues can undergo modiﬁcation at the site
of injection, so the relevance of proliferative effects
identiﬁed in vitro to in vivo risks is questionable. There
are, nevertheless, several observational epidemiological
studies that link use of some insulin analogues with
increased risk of cancer [98,104,108,109]. Although
controversial [110,111], the possibility has been raised
that the pro-proliferative effects of insulin analogues
result primarily from enhanced activation of the IGF-1
(insulin-like growth factor-1) receptor [21]. Their
relevance to any effects native human insulin may have
are, therefore, questionable.
It should be noted that the other major therapy option
for increasing circulating native insulin levels is use of
insulin secretagogues, of which the sulfonylurea drugs
have been available the longest. There is some evidence
suggesting an increased risk of cancer in patients using
theseagents[97–99,112],butﬁrmconclusionsaredifﬁcult
because of the inclusion of reduced risk metformin users
in the comparison groups. Sulfonylurea users may be
at a somewhat lower risk than insulin users [97], but
information in this area is very limited and, even if an
increased risk was conﬁrmed, a pharmacological effect of
these drugs cannot be excluded.
MITOGENIC AND ANTI-APOPTOTIC EFFECTS
OF INSULIN
Growth promotion via classical insulin
signalling
The possibility that insulin might increase cell prolif-
eration in vivo was highlighted decades ago by Stout
and Vallance-Owen [113] in relation to the development
of atherosclerosis and, at the same time, in vitro and
in vivo studies were indicating that many tumours might
have an absolute dependence on insulin for continuing
growth [114,115]. Since then, there has been considerable
progress in elucidating how insulin could promote cell
proliferation and survival. Insulin action begins with
bindingtoitsspeciﬁcreceptor,atransmembranereceptor
tyrosine kinase. Signalling by the activated receptor
involves autophosphorylation of tyrosine residues in
the intracellular domain, which then promotes the
phosphorylation of IRS-1 (insulin receptor substrate-1)
and transmission of the insulin signal via two major
phosphorylation cascades. These are distinguished by
their principal mediators: PI3K (phosphoinositide 3-
kinase) and MAPK (mitogen-activated protein kinase),
as illustrated in Figure 1.
Signalling via the PI3K pathway involves the
interaction of phosphorylated IRS-1 with the p85
regulatory subunit of PI3K and, as a consequence,
activation of the PI3K p110 catalytic subunit. Activated
PI3K locates to the cell membrane where it catalyses the
production of PtdIns(3,4,5)P3. PtdIns(3,4,5)P3 stimulates
the translation of the serine/threonine protein kinase
Akt to the cell membrane, where it is phosphorylated
by the PtdIns(3,4,5)P3-dependent protein kinase PDK1
(phosphoinositide-dependent kinase 1). Akt is capable
of stimulating the phosphorylation and consequent
inhibition or activation of a broad range of proteins that
affectcellgrowth,divisionandsurvivalaswellaslipidand
carbohydrate metabolism, for example the pro-apoptotic
Bcl-2 family member BAD, the metabolism and growth-
related Fox (forkhead box) transcription factors such as
Foxa2 and FOXO1a, and the growth-related mTOR and
its downstream effector kinase p70S6K (p70 S6 kinase).
Signalling via the PI3K pathway is also a key factor
in the translocation of GLUT-4 glucose transporters
to the cell membrane. The importance of signalling via
the PI3K pathway for cell proliferation and survival is
evidenct from the high prevalence in a variety of cancers
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Figure 1 Principal signalling pathways activated by the insulin receptor
Positive inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars. MEK, MAPK/extracellular-signal-regulated kinase kinase; PIP3,
PtdIns(3,4,5)P3; PKC, protein kinase C; triglyceride, triacylgycerol.
of a loss-of-function of the PtdIns(3,4,5)P3-phosphatase
PTEN (phosphatase and tensin homologue deleted on
chromosome 10), which results in elevated levels of
PtdIns(3,4,5)P3 and enhanced PI3K signalling [116].
Phosphorylated IRS-1 can also mediate the formation
of a complex between the adaptor protein Grb2 (growth-
factor-receptor-bound protein 2) and the guanine
nucleotide-exchange factor mSos (mammalian Son of
sevenless). The Grb2–mSos complex can then promote
GTP loading and consequent activation of the small-
molecular-mass GTPase p21Ras, which lies at the head
of the MAPK signalling cascade and which provides
a point of convergence for signalling by a number of
growth factors. Via a series of intermediate kinases,
activated p21Ras promotes the activation of MAPKs,
which then activate transcription factors involved in
cell proliferation. The importance of signalling via the
Ras/MAPK pathway for cell proliferation and survival is
shown by the high prevalence of p21Ras overexpression
in a range of different cancers [117].
In vitro studies, including studies of cancer cells
[118], provide ample evidence for the promotion of
cell division by insulin. However, supra-physiological
insulin concentrations have generally been used in these
studies and it has been questioned whether, on its own,
insulin binding to the insulin receptor has any growth-
promoting effects [119]. Nevertheless, the in vivo milieu
in which insulin operates may be very different from in
vitro conditions and, as will be shown, insulin can induce
other changes that could amplify any growth-promoting
properties it may have. It could be objected that the
compensatory hyperinsulinaemia of insulin resistance
merely restores insulin signalling to non-resistant levels
so, in principle, no additional drive to cell division and
survival might be expected. This is likely to be true of
signalling via the PI3K pathway, which also mediates the
glucoregulatory effects of insulin. There is, nevertheless,
someevidencefromaninvitrostudyinbreastcancercells
thatinsulinsignallingviatheMAPKpathwayispreserved
despite inhibition of IRS-1/PI3K signalling [120]. The
possibility that compensatory hyperinsulinaemia might
provide additional drive to cell proliferation via the
MAPK pathway is illustrated in Figure 2.
Other growth-promoting effects of insulin
Small-molecular-mass GTPases play a key role in the
signalling pathways involved in cell proliferation and
there is evidence, largely from the work of Goalstone,
Drazninandco-workers[121–123],forspeciﬁcactivation
of these proteins and ampliﬁcation of their effects by
insulin. p21Ras is among the most prominent of these
enzymes and prenylation of p21Ras with a farnesyl
moiety by the enzyme farnesyl transferase is an essential
step in anchoring p21Ras to the plasma membrane in
readiness for GTP loading and signalling via the MAPK
pathway. Insulin can activate farnesyl transferase by
phosphorylation of its regulatory α subunit [121], and
insulin-induced increases in p21Ras farnesylation have
indeed been shown to be associated with increased GTP
loading of membrane-bound p21Ras [122]. Activation of
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Figure 2 Hypothetical scheme for enhanced cell growth and survival in insulin resistance
In uncompensated insulin resistance (upper panel), signalling via the PI3K pathway is diminished, glucose uptake by the cell via GLUT-4 transporters is reduced,
suppression of gluconeogenesis is reduced and glucose levels rise. In compensated insulin resistance (lower panel), the pancreas responds to the rise in glucose levels
with increased insulin secretion, insulin levels rise, signalling through the PI3K pathway is restored and cell glucose uptake and gluconeogenesis are normalized.
However, the increased insulin concentrations increase signalling via the kinases of the MAPK pathway {p21Ras, Raf, MEK [MAPK/ERK (extracellular-signal-regulated
kinase) kinase] and ERK} to increase cell proliferation and survival.
farnesyl transferaseappears to be mediated via the insulin
receptor, as shown by increased levels of farnesylated
p21Ras in cells overexpressing insulin receptors and
reducedlevelsincellsexpressingamutantinsulinreceptor
with impaired function [123]. These studies also suggest
that farnesyl transferase activation by insulin is not
mediated by the IRS-1/PI3K pathway, but via another
target of the activated insulin receptor, Shc, which then
promotes Grb2/mSos recruitment, p21Ras activation
and phosphorylation of farnesyl transferase via MAPK
pathway activation. Different isoforms of Shc that can
be phosphorylated by the activated insulin receptor
[124] include the p52 isoform which, upon tyrosine
phosphorylation, activates p21Ras and the p66 isoform
which has an additional domain with a phosphorylatable
serine residue and acts as a competitive inhibitor of
p21Ras activation by the other isoforms [125].
This stimulation of farnesyl transferase activity
appears to be speciﬁc to insulin [126], and prolonged
hyperinsulinaemiahasbeenshowntoincreasethecellular
pool of farnesylated p21Ras and loading of p21Ras with
GTP[127,128].Thiseffectisinadditiontothegeneralup-
regulation of p21Ras-GTP associated with growth factor
signallinganditcan,therefore,synergizewithstimulation
of the guanine nucleotide-exchange activity of mSos by
insulin or other growth factors to amplify growth factor
signalling [129,130]. These interactions are illustrated in
Figure 3.
Up-regulation of insulin receptors and
insulin-regulated intracellular signalling
molecules
Carcinogenesis is a multifactorial multistage process
and one of these stages can include overexpression of
insulin receptors. The compensatory hyperinsulinaemia
of insulin resistance could, therefore, provide an
additional stimulus to cell proliferation and survival
in situations where insulin signalling has already been
rendered hypersensitive by increased expression of
insulin receptors. In non-malignantly transformed cells
overexpressing insulin receptors, exposure to insulin can
result in a malignantly transformed phenotype [131,132].
Insulinreceptorsmaybeoverexpressed2–6-foldincancer
cells [133–135]; moreover, although the up-regulated
receptors can appear structurally normal, the sensitivity
of their receptor tyrosine kinase activity is increased
[136]. Two isoforms of the insulin receptor exist, the A
isoform predominating in fetal tissues and the B isoform
in adult tissues. In addition to binding insulin, the A
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Figure 3 Farnesylation of p21Ras causes it to locate to the plasma membrane where it can undergo GTP loading, which is
essential for signalling via the MAPK pathway
Insulin increases activation of farnesyl transferase, which increases farnesylation of p21Ras. As a consequence, the pool of p21Ras-GTP is increased. This has the effect
of amplifying growth factor signalling via the MAPK pathway. MEK, MAPK/ERK kinase.
form of the receptor binds IGF-2 and, in cancer cells
overexpressing insulin receptors, the A form appears to
predominate [137]. Overexpression of insulin receptors
thereforeexposesthecelltothegrowth-promotingeffects
of IGF-2.
Cancer cells appear to loose their ability to down-
regulate insulin receptors in response to hyperinsulin-
aemia [138] and in cells with up-regulated insulin
receptors, a given concentration of insulin can increase
production of p21Ras-GTP 7-fold compared with
normal cells [139]. The observation that p21Ras-GTP,
farnesylated p21 Ras and phosphorylated Shc are all
increased in cells overexpressing insulin receptors or
overexpressing a mitogenically active mutant insulin
receptor emphasizes the functional consequences of
receptor overexpression [135,140]. As well as interacting
with up-regulated insulin receptors, the compensatory
hyperinsulinaemiaofinsulinresistancecouldalsointeract
withtheup-regulationofintracellularmediatorsinvolved
in growth factor signalling frequently observed in
carcinogenesis. An example is provided by p21Ras itself,
which,whenoverexpressed,cangreatlyenhancetheeffect
of insulin on cell growth [141].
INSULIN RESISTANCE, HYPERINSULINAEMIA
AND SIGNALLING VIA THE IGF-1 RECEPTOR
IGF-1, insulin resistance and cell
proliferation and survival
IGF-1 signalling via the IGF-1 receptor has effects
on cell proliferation and survival that are appreciably
stronger than those of insulin [142]. IGF-1 can act as
a potent growth factor for cancer cells both in vivo
[143] and in vitro [144], and in vivo overexpression of
IGF-1 can promote tumour formation [145], whereas its
down-regulation can inhibit tumorigenesis [146]. IGF-1
can overcome the beneﬁcial effect of calorie restriction
in animal models of cancer [147] and can increase
expression of angiogenic factors in cancer cells [148].
Epidemiological evidence supports a role for elevated
circulatingIGF-1levelsinthedevelopmentofavarietyof
cancers, including colorectal, prostate and breast cancers
[149] (although an inverse relationship has been reported
for free IGF-1 levels [67]). It should also be noted
that stimulation of PI3K or MAPK signalling via the
IGF-1 receptor can promote phosphorylation of TAF-1
(transcriptional activation function-1) of the oestrogen
receptor, thus promoting oestrogen-independent cell
growth and division in oestrogen-sensitive tissues [150].
There is considerable homology between the insulin
receptor and the IGF-1 receptor, and insulin can bind to
and activate the IGF-1 receptor. Insulin could, therefore,
enhanceIGFsignallingbydirectstimulationoftheIGF-1
receptor [151], although the relevance of this is uncertain
[152]. Nevertheless, given that signalling via the IGF-1
receptor is more tightly linked to growth promotion,
anyaugmentationofIGF-1-receptor-mediatedsignalling
could markedly affect cell proliferation and survival. In
accordance with this, relatively minor increases in serum
IGF-1 concentrations are associated with an increased
risk of prostate [153,154], breast [155], colon [156] and
lung [157] cancers.
Indirect effects of insulin on IGF signalling
Insulin can up-regulate human hepatic GH (growth
hormone) receptors [158], and receptor-mediated GH
signalling in the liver is the principal stimulus for IGF-1
release [159]. Hyperinsulinaemia could, therefore, spe-
ciﬁcally augment IGF-1 levels. The potential importance
of such an effect is suggested by the observations that, in
contrastwithIGF-1,IGF-2levelsappeartobeunaffected
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Figure 4 Interaction between insulin resistance and cell proliferation and survival
Theoretically, interactions between the effects of insulin resistance and hyperinsulinaemia could lead to ampliﬁcation of the cell proliferation and survival signals induced
by insulin. This ampliﬁcation will be even greater against a background of insulin or IGF-1 receptor overexpression or growth signalling protein overexpression. The
ability of insulin to increase the pool of p21Ras-GTP by enhancing p21Ras farnesylation has the potential to amplify further these effects.
by GH levels [160] and do not predict incident cancer
[156]. As IGF-1 signalling involves similar pathways
to those utilized by insulin, another mechanism by
which insulin could amplify IGF-1 signalling could
involveinsulin’sabilitytostimulatep21Rasfarnesylation.
Moreover,aswiththeinsulinreceptor,theIGF-1receptor
is frequently overexpressed in cancer cells [161,162]. In
addition to amplifying any signalling by insulin via the
IGF-1 receptor, overexpression of the IGF-1 receptor
in cancer cells will augment the formation of insulin
receptor/IGF-1 receptor hybrids. This could increase the
possibility of cross-talk, whereby insulin binding
totheinsulinreceptormoietyoftheheterodimeractivates
theIGF-1receptormoiety[163],andthereisevidencefor
this in relation with hybrids with the A isoform of the
insulin receptor [164].
IGFBPs (IGF-binding proteins)
Insulin could affect IGF-1 signalling further by
modulating the availability of IGFBPs. Six IGFBPs have
been identiﬁed and the most abundant, IGFBP-3, binds
approx. 80% of circulating IGF-1 and has intrinsic
anti-tumorigenic properties [165], possibly mediated
by inhibition of farnesyl transferase activity [166].
There is also evidence that IGFBP-3 may promote
apoptosis [167,168]; however, hepatic production of
IGFBP-3andformationoftheIGF-1–IGFBP-3complex
appears to be positively controlled by GH, which,
given the up-regulation of GH receptors by insulin
described above, would predict higher IGFBP-3 levels
in association with compensatory hyperinsulinaemia
[169]. These interactions would then suggest an anti-
tumorigenic action of insulin.
In contrast, hyperinsulinaemia suppresses IGFBP-1
levels [170,171] and, although IGFBP-2 is not
acutely regulated by insulin, there is some evidence
that chronically low levels of insulin are associated
with an increase in IGFBP-2 [172]. How important
these effects are with regard to the control of IGF
availability might be questioned given that less than
25% of IGF appears to be bound by these proteins
[173]. However, although IGFBP-3 is responsible for
the bulk of IGF binding, it is the smaller, capillary
permeable, rapidly turning over pool of IGFBPs, which
includes IGFBP-1 and IGFBP-2, that may be important
in modulating IGF bioactivity [173,174]. Suppression of
the levels of these proteins by insulin might, therefore,
increase the extravascular availability of bioactive IGF-1,
although much more evidence is needed to clarify the
complex dynamic relationships that are likely to be
involved.
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Figure 5 Coincident promotion of insulin resistance and cell proliferation and survival in inﬂammation
Activated cells of the immune system release cytokines and ROS, which induce insulin resistance via JNK and cell proliferation and survival via NF-κB. Positive
inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars.
INSULIN-RESISTANCE-RELATED
PRO-CARCINOGENIC CHARACTERISTICS
Insulin resistance and its compensatory hyperinsulin-
aemia have effects that can promote cancer and
these effects can interact and synergize with other
growth-promoting changes, as illustrated in Figure 4.
Nevertheless, insulin resistance and hyperinsulinaemia
may be a consequence of other processes that can
themselves promote cancer by other pathways. Two
key areas in this respect are increased activation of
the inﬂammatory system and increased adiposity, both
of which can induce insulin resistance and both of
which may promote the development and progression
of cancer independently of their effects on insulin
resistance.
Activation of inﬂammatory mediators
Inﬂammation, chronic and subclinical, has come to be
recognized as a key factor in tumorigenesis and cancer
progression [175–177]. One means by which activated
cells of the immune system exert their protection against
pathogens is by production of ROS (reactive oxygen
species), and ROS can disrupt insulin signalling by
activating JNK (c-Jun N-terminal kinase). JNK, in turn,
increases the serine phosphorylation of IRS-1, decreases
thetyrosinephosphorylationofIRS-1andinhibitsserine
phosphorylation of Akt, each of which contribute to
reduced insulin signalling [178]. ROS can also cause
oxidative damage to DNA, a key factor in the somatic
mutations that underlie tumorigenesis [179]. It should
be noted that, as well as inducing insulin resistance,
production of ROS can also be increased by some of the
consequences of insulin resistance, including elevations
in glucose levels [180] and increased β-oxidation of fatty
acids [181].
Activation of inﬂammatory pathways can induce
insulin resistance by a variety of other mechanisms [182].
For example, signalling by TNF-α (tumour necrosis
factor-α)viatheTNFreceptorcanactivateJNK.Another
possibility involves signalling via NF-κB (nuclear factor
κB), which is promoted by an inhibitor of NF-κB
inactivation, IKKβ [IκB (inhibitor of NF-κB) kinase β].
The importance of NF-κB in the induction of insulin
resistance is apparent in the improvements in insulin
sensitivity resulting from inhibition of IKKβ by high
dose salicylate [183]. Equally, the importance of NF-
κB in the promotion of carcinogenesis is apparent in
the reduction in risk of cancer associated with the
use of aspirin and other NSAIDs (non-steroidal anti-
inﬂammatory agents) [184], which is mediated by the
inhibition of signalling via NF-κB [185]. A further
convergence between inﬂammation, insulin resistance
and cancer is observed in relation to the nuclear receptor
PPAR-γ (peroxisome-proliferator-activated receptor-γ).
Asawell-establishedmediatorofinsulinaction,PPAR-γ
can also antagonize NF-κB [186] and can inhibit pro-
carcinogenic changes in human colon cancer cells [187].
Interactions between inﬂammation, insulin resistance
and cell proliferation and survival are illustrated in
Figure 5.
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Figure 6 Coincident promotion of insulin resistance and cell proliferation and survival in obesity
Positive inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars.
Obesity
Increased adiposity is a major determinant of insulin
resistance, as well as being a risk factor for cancer.
It is associated with increased NEFAs (non-esteriﬁed
fatty acid levels) which, by competing with glucose as
a metabolic fuel, can induce insulin resistance and can
alsoincreasefattyacidoxidationandproductionofROS.
Moreover, adipose tissue, with its resident macrophages,
can release a variety of so-called ‘adipokines’ that include
both proteins with signalling properties and cytokines.
The cytokines include TNF-α and IL-6 (interleukin-6),
both of which have pro-oncogenic effects and can induce
insulin resistance [188]. Visceral adipose tissue appears
to be a particularly rich source of adipokine cytokines
[189], and insulin resistance has a stronger relationship
with visceral fat than with overall adiposity. Visceral fat
mayparticularlypredisposetothedevelopmentofcancer
[3,190], especially in post-menopausal women [191–193].
Among the adipokine proteins with signalling proper-
ties, leptin acts as an ‘adipostat’ by suppressing centrally
generated appetite signalling. Obesity is, however,
associated with leptin resistance and hyperleptinaemia.
Leptinconcentrationsarestronglycorrelatedwithinsulin
resistance[194],butleptinappearstohavepro-oncogenic
effects of its own since, in vitro, it can enhance
proliferation of both normal [195] and cancer [196] cell
lines and can stimulate angiogenesis [197]. Moreover, at
levelsobservedinobesity,leptinmaybeabletoinducethe
adipose tissue aromatase enzyme complex [198], which
would be expected to increase concentrations of the
mitogenic sex hormone oestradiol (see below).
Obesity is also associated with reduced levels of the
anti-inﬂammatory pro-apoptotic adipokine adiponectin.
Adiponectinisinverselyassociatedwithinsulinresistance
and this may reﬂect more than mere co-variation with
adiposity, since adiponectin has a number of effects at
the cellular level that could increase the sensitivity of
glucose and lipid metabolism to insulin via its activation
of the cell energy sensor AMPK and the nuclear receptor
PPAR-α [199]. As mentioned previously with regard to
metformin, activation of AMPK has anti-proliferative
effects, and there is evidence for this in relation to the
activation of AMPK signalling by adiponectin [200]. It
should be noted that adiponectin can inhibit TNF-α-
inducedphosphorylationofIKKβ and,consequently,the
activation of NF-κB [201].
Beyond the pro-inﬂammatory effects of increased
adiposity, adipose tissue can mediate potentially pro-
oncogenictransformationsingonadaloradrenalsteroids:
speciﬁcally, increased synthesis of oestradiol from
testosterone and oestrone from  4-androstenedione by
the aromatase enzyme complex. This increases oestradiol
concentrations, and oestradiol is a potent mitogen for
breast and endometrial tissue. The potential importance
of these interconversions is apparent in post-menopausal
women, in whom oestradiol levels are signiﬁcantly
correlated with BMI (body mass index), and the risk of
breastcancerassociatedwithBMIissubstantiallyreduced
by including endogenous oestrogen concentrations as
a covariate [202]. Interactions between obesity, insulin
resistanceandcellproliferationandsurvivalareillustrated
in Figure 6.
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Other factors related to insulin resistance
and cancer
Speciﬁcally with regard to the sex-hormone-dependent
cancers, i.e. cancers of the breast, prostate and endo-
metrium, SHBG (sex hormone-binding globulin) levels
are reduced in states of insulin resistance, apparently
due to a direct suppressive effect of hyperinsulinaemia
on SHBG production by the liver [203]. This could act
to increase the availability of free sex hormones [204]
and, therefore, favour the development of sex-hormone-
dependent cancers. Ampliﬁcation of oestradiol levels in
obesity could also result from induction of aromatase
activity by the pro-inﬂammatory adipokines TNF-α and
IL-6 [205], which, as mentioned above, will be present in
adipose tissue in relatively high concentrations.
Increased inﬂammation and obesity and decreased
SHBG provide extracellular points of focus that relate
to insulin resistance and have pro-carcinogenic effects
of their own. Conversely, there are several intracellular
pointsoffocusthatcanbothmediateinsulinsensitization
and diminish cell proliferation and survival. PPAR-γ
has already been mentioned in relation to inﬂammation.
Another, more recently recognized point of focus
is provided by the deacetylase SIRT1 (sirtuin 1).
Sirtuins are key mediators in the longevity associated
with calorie restriction [206], and sirtuin action can
modulatetheactivitiesofseveralkeytranscriptionfactors
(reviewedin[207,208]).Forexample,SIRT1candiminish
inﬂammatory pathway signalling by deacetylating the
p65 transcription factor subunit of NF-κB and can
deacetylate Foxo1, thus promoting transcription of the
adiponectin gene. It can also promote deacetylation
of Foxo3a, leading to enhanced expression of catalase,
the enzyme responsible for metabolizing H2O2 and
thus reducing ROS levels. SIRT1 can also enhance
post-receptor insulin signalling by increasing serine
phosphorylation of Akt and tyrosine phosphorylation
of the insulin receptor and IRS-1, primarily through
transcriptional repression of the phosphorylase Ptpn1
(protein tyrosine phosphatase, non-receptor type 1). The
actions of SIRT1 appear to depend on the nutritional
context in which they are studied, but their net effects
generally point to enhancement of insulin sensitivity.
Their effect on cancer risk is complicated by the fact
that, under normal conditions, there is a mutually
reinforced inverse relationship between SIRT1 and p53
[209,210]. Given the critical role of p53 in eliminating
DNA damage via apoptosis, its down-regulation would,
conventionally, be regarded as oncogenic. However,
SIRT1 can also inhibit cell cycle progression [211], so
it may be that it acts to provide a check on both
cell cycle progression and apoptosis, thus allowing
for more effective DNA repair [207]. In accord
with this, in vivo studies show a tumour-suppressive
effect of experimentally enhanced SIRT1 levels
[212].
DISCUSSION
There are plausible mechanisms by which insulin
resistance and hyperinsulinaemia could promote cancer
development and progression, but it remains to be
established how important these are. A number of
conditions that lead to insulin resistance, particularly
subclinical inﬂammation and obesity, have effects of
their own that are pro-carcinogenic. Therefore, in
epidemiological studies, detailed baseline and long-term
evaluation will be needed not only of insulin resistance
and hyperinsulinaemia, but also subclinical inﬂammation
and adiposity. To date, very few studies meet these
requirements.
The inter-relatedness of the various factors that
connect with insulin resistance and cancer risk is
illustrated in Figure 7, and it should be apparent
from this Figure that it may be unrealistic to consider
insulin resistance as a standalone cancer risk factor. Both
inﬂammation and obesity have effects of their own
that could promote cancer, but the hyperinsulinaemia
they induce may itself feedback and augment further
their effects on cell proliferation and survival. One
possibility for gaining a better understanding of the
relative importance of the role of insulin resistance
in cancer development may be to evaluate the co-
associated metabolic disturbances that insulin resistance
is characterized by, rather than insulin resistance itself.
Conventionally, insulin resistanceis quantiﬁed according
to its glucoregulatory effects, but it also has effects
on lipid metabolism and renal function. A measure
of the insulin resistance syndrome could, therefore,
provide a potentially useful index of whole-body insulin
resistance. Given the close relationship between insulin
resistance and hyperinsulinaemia, such a measure could
also provide a better index of net insulin exposure than
a single fasting insulin measurement or even insulin
concentrations in response to glucose challenge. It is
worth noting, as described above, that the evidence
for the metabolic syndrome (an approximate index of
insulin-resistance-relatedmetabolic disturbance)as arisk
factor for cancer is more consistent than for insulin
alone.
An important question that has yet to be resolved
is, to what extent is insulin resistance a risk factor for
cancer in general or for speciﬁc types of cancer? As
mentioned, there is some evidence for insulin resistance
being particularly related to colorectal cancer, and
studies speciﬁcally concerned with colorectal cancer
predominate. However, the majority of mechanisms
summarized in the present review could affect the risk
of any kind of cancer, with some additional mechanisms
applying to sex-hormone-dependent cancers. Colorectal
cancer is, nevertheless, a major cancer and insulin-
resistance-related factors could provide useful points of
intervention by analogy with cigarette smoking and lung
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Figure 7 Selected key inter-relationships in an insulin-resistant pro-carcinogenic state associated with increased
inﬂammation, obesity and reduced levels of SIRT1
Potentially beneﬁcial effects, with regard to reducing both insulin resistance and cell proliferation and survival, that are diminished in this state are shown by the broken
lines. Positive inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars. Variables independently reduced in insulin-resistant
states are shown by the solid arrows.
cancer, and sex hormone action and breast and prostate
cancer.
Recent reports of an increased incidence of cancer in
users of insulin analogues [98,104,108,109] highlight the
potential importance of insulin as a cancer risk factor.
However, from the clinical point of view, these are still
preliminaryobservations,withrelativelyshortfollow-up
times and inconsistencies in the types of cancer for which
an increased risk was apparent. Future studies will need
to focus on whether these are chance ﬁndings, whether
they reﬂect the inﬂuence of a particular at-risk subgroup
and, supposingthere is increased risk,whether this places
incidence rates among those using long-acting insulins
above those in the population in general. This latter point
reﬂects the possibility mentioned previously that some
patientswithdiabetesmayberelativelyhypoinsulinaemic
and, therefore, at relatively low risk of cancer. If such
patients form the comparison group in studies of long-
acting insulins, an exaggerated impression of risk may be
given.
In conclusion, it bears repeating that cancer is a
multifactorial process. Insulin itself does not induce
somatic cell mutations and cannot, therefore, be
considered a carcinogen. However, pre-malignant lesions
may be present in a high proportion of healthy
individuals, and whether these progress to an invasive
metastatic fatal cancer can depend on an extraordinarily
complex interacting network of errors, imbalances
and disturbances. It should be apparent from the
present review that insulin resistance and its associated
hyperinsulinaemiacouldformasigniﬁcantstrandinsuch
an e t w o r k .
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